Although esophageal cancer comprises a small percentage (1.5%) of total cancer cases in the United States, mortality rate remains high. In the United States, an estimated 16,980 cases of esophageal cancer will be diagnosed in 2015 and 15,590 deaths are expected from the disease [1,2]. Regardless of histology, approximately 50-60% of patients present with incurable locally advance or metastatic disease. As such, at most 10-15% of all patients presenting with esophageal cancer are cured [3]. For those with locally advanced, non-metastatic disease, cure is achieved in up to 40% of patients when multimodality therapy is used [4,5].
AbstractBackground: The treatment of resectable stages of esophageal cancer often involves pre-operative concurrent chemoradiotherapy. This study aims to evaluate the effect of cisplatin/5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.